Veraxa Biotech Completes SPAC Merger with Voyager Acquisition Corp. and Lists on Nasdaq

Veraxa Biotech AG has completed its business combination with Voyager Acquisition Corp., a special purpose acquisition company, and will begin trading on the Nasdaq Capital Market under ticker symbols "VRXA" and "VRXAW" on June 11, 2026. The transaction creates a publicly traded biopharmaceutical company focused on next-generation cancer therapies, including bispecific T-cell engagers and antibody-drug conjugates using Veraxa's proprietary BiTAC platform. The company has secured $27.5 million in senior secured note financing and a $50 million share purchase agreement to advance its oncology pipeline. The merger was approved by shareholders of both companies earlier in 2026. Veraxa recently presented promising data supporting its BiTAC platform at the American Association for Cancer Research 2026 Annual Meeting.